RODRIGO SOUZA
Biocatalysis and Organic Synthesis Group, Chemistry Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

Crinecerfont is an orally administered, nonsteroidal corticotropinreleasing factor type 1 (CRF1) receptor antagonista, sold under the brand name Crenessity, approved for medical use by the FDA in December 2024 for the treatment of classic congenital adrenal hyperplasia (CAH). By selectively inhibiting CRF1, Crinecerfont reduces excessive adrenocorticotropic hormone (ACTH) drive and lower the overproduction of adrenal androgens that is characteristic of CAH and it considers to be a first-in-class medicine.

Crinecerfont was developed by Neurocrine Biosciences, a San Diegobased biopharmaceutical company founded in 1992. Neurocrine specializes in discovering and developing treatments in neurology, endocrinology, and psychiatry. While Neurocrine has a history of multiple collaborations and compound in-licensing deals over the decades, Crinecerfont (NBI74788) can be described as an inhouse discovery or an internally led development from its broader CRF antagonist ... ...